Immutep Limited Stock Deutsche Boerse AG
Stocks
YP1A
US45257L1089
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
22:15:31 25/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.120 EUR | -0.96% |
|
-9.65% | -91.83% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 50.11M 35.16M 30.93M 29.25M 26.53M 49.82M 3.38B 350M 135M 1.72B 132M 129M 5.54B | P/E 2027 * |
-2x | P/E 2028 * | -3.09x |
|---|---|---|---|---|---|
| Enterprise Value | -4.49M -3.15M -2.77M -2.62M -2.38M -4.47M -303M -31.4M -12.13M -154M -11.84M -11.58M -496M | EV / Sales 2027 * |
-1.12x | EV / Sales 2028 * | 5.42x |
| Free-Float |
96.92% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IMMP | Delayed | |
CBOE
| IMMP | Real-time | |
|
Deutsche Boerse AG
| YP1A | Delayed | |
|
Tradegate
| YP1A | Real-time | |
|
Börse Stuttgart
| YP1A | Delayed |
| 1 day | -0.96% | ||
| 1 week | -9.65% | ||
| Current month | -33.55% | ||
| 1 month | -33.55% | ||
| 3 months | -39.05% | ||
| 6 months | -29.45% | ||
| Current year | -91.83% |
| 1 week | 0.21 |  | 4.68 |
| 1 month | 0.21 | | 6.2 |
| Current year | 0.21 | | 52.8 |
| 1 year | 0.21 | | 58.4 |
| 3 years | 0.21 | | 60 |
| 5 years | 0.21 | | 85.6 |
| 10 years | 0.21 | | 134 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.96% | -9.65% | - | - | 37.26M | |
| +2.64% | +7.07% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +0.40% | +49.94% | +37.06% | 44.5B | |
| -1.58% | +4.66% | +337.90% | +614.38% | 43.93B | |
| +1.70% | +0.36% | +10.27% | +99.27% | 41.03B | |
| +0.51% | -0.61% | +5.18% | +46.87% | 29.85B | |
| -0.48% | -1.32% | +23.00% | +150.01% | 17.27B | |
| +0.08% | +9.03% | +8.29% | - | 15.34B | |
| +1.76% | +2.98% | +29.13% | +45.78% | 15.3B | |
| +1.97% | -3.17% | - | - | 14.82B | |
| Average | +0.51% | +2.46% | +59.45% | +147.39% | 30B | |
| Weighted average by Cap. | +0.67% | +2.97% | +75.17% | +163.62% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4M 2.81M 2.47M 2.33M 2.12M 3.98M 269M 27.95M 10.8M 138M 10.54M 10.31M 442M | 3M 2.11M 1.85M 1.75M 1.59M 2.98M 202M 20.97M 8.1M 103M 7.9M 7.73M 331M |
| Net income | -26.1M -18.32M -16.11M -15.23M -13.82M -25.95M -1.76B -182M -70.44M -897M -68.77M -67.28M -2.88B | -30.47M -21.39M -18.81M -17.79M -16.13M -30.3M -2.05B -213M -82.25M -1.05B -80.29M -78.56M -3.37B |
| Net Debt | -54.6M -38.32M -33.7M -31.87M -28.91M -54.28M -3.68B -382M -147M -1.88B -144M -141M -6.03B | -33.83M -23.74M -20.88M -19.75M -17.91M -33.64M -2.28B -236M -91.32M -1.16B -89.15M -87.22M -3.74B |
| Date | Price | Change |
|---|---|---|
| 25/09/26 | €4.120 | -0.96% |
| 24/09/26 | €4.160 | -0.95% |
| 23/09/26 | €4.200 | -6.25% |
| 22/09/26 | €4.480 | -4.27% |
| 21/09/26 | €4.680 | +2.63% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
- YP1A Stock
Select your edition
All financial news and data tailored to specific country editions
